GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » G1 Therapeutics Inc (STU:G1H) » Definitions » Tax Expense

G1 Therapeutics (STU:G1H) Tax Expense : €1.68 Mil (TTM As of Jun. 2024)


View and export this data going back to 2018. Start your Free Trial

What is G1 Therapeutics Tax Expense?

G1 Therapeutics's tax expense for the months ended in Jun. 2024 was €0.00 Mil. Its tax expense for the trailing twelve months (TTM) ended in Jun. 2024 was €1.68 Mil.


G1 Therapeutics Tax Expense Historical Data

The historical data trend for G1 Therapeutics's Tax Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

G1 Therapeutics Tax Expense Chart

G1 Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Tax Expense
Get a 7-Day Free Trial Premium Member Only - 1.16 0.82 1.61 2.86

G1 Therapeutics Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Tax Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.21 0.85 0.83 - -

G1 Therapeutics Tax Expense Calculation

Tax paid by the company. It is computed in by multiplying the income before tax number, as reported to shareholders, by the appropriate tax rate. In reality, the computation is typically considerably more complex due to things such as expenses considered not deductible by taxing authorities ("add backs"), the range of tax rates applicable to various levels of income, different tax rates in different jurisdictions, multiple layers of tax on income, and other issues.

Tax Expense for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €1.68 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


G1 Therapeutics  (STU:G1H) Tax Expense Explanation

In the long run, income before tax and taxable income will likely be more similar than they are in any given period. If the one is less in earlier years, then it will be greater in later years. Deferred taxes will reverse themselves in the long run and in total will zero out, unless there is something like a change in tax rates in the intervening period. A deferred tax payable results from a tax break in the early years and will reverse itself in later years; a deferred tax receivable results from more taxes being paid in early years than the tax expense reported to shareholders and will again reverse itself in later years. The deferred tax amount is computed by estimating the amount and the timing of the reversal and multiplying that by the appropriate tax rates.


G1 Therapeutics Tax Expense Related Terms

Thank you for viewing the detailed overview of G1 Therapeutics's Tax Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


G1 Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
700 Park Offices Drive, Suite 200, Research Triangle Park, NC, USA, 27709
G1 Therapeutics Inc is a commercial-stage biopharmaceutical company. It is engaged in developing novel, small-molecule therapies to target unmet needs in the treatment of cancer. The firm is developing drugs that have the potential to treat the types of cancer, such as cell lung cancer and breast cancer, and designs them to combine and enhance the anti-tumor activity of current therapies. Its product COSELA indicates to help protect bone marrow from the damage of chemotherapy.

G1 Therapeutics Headlines

No Headlines